OCS-01 eye drops demonstrated positive topline results for the treatment of inflammation and pain after cataract surgery, according to a press release from Oculis.
The double-masked, placebo-controlled phase 3 OPTIMIZE trial included 119 participants who received a once-daily drop of high-concentration dexamethasone compared with 122 participants who received vehicle for 14 days after cataract surgery.
The trial met both primary efficacy endpoints. At day 15, 57.2% of those who received OCS-01 experienced no inflammation compared with 24% of those who received vehicle, while at day 4, 75.5% of